3 yr interim RELIANCE study analysis shows long-term CAN tx is safe and effective in CAPS regardless of the underlying mutation and TRAPS. Abs 0812 #ACR22 @RheumNow t.co/pgSq1IICJK and
3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry - ACR Meeting Abstracts
Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) - Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis - ACR Meeting Abstracts
